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ABSTRACT
Introduction. Acute kidney injury (AKI) 
is a life-threatening syndrome caused by 
a sudden and rapidly progressing impair-
ment of renal function. It is a common and 
complicated clinical entity among hospi-
talized children, occurring in 2%-4.5% of 
children treated in a pediatric intensive 
care unit. Mortality among such patients 
remains high (from 8% to 89%) despite 
improving patient care and technical pos-
sibilities. The stage of renal damage is a 
reversible process, and its timely detection 
would prevent the progression of renal 
damage and thus reduce pediatric mor-
tality rates. Therefore, modern medicine 
necessitates the identification of novel AKI 
biomarkers that would correlate with renal 
cell damage and could be detected ear-
lier than a rise in serum creatinine (sCr). 
Neutrophil gelatinase-associated lipocalin 
(NGAL) and interleukin 18 (IL-18) are one 
of such early markers of AKI.
Aim. To carry out a literature review of 
studies on changes in NGAL and IL-18 lev-
els in the urine of critically ill patients and 
to determine a prognostic value of these 
biomarkers in the detection of renal injury 
and impact on disease outcomes.
Material and methods. This literature 
review includes the publications of bio-
medical studies assessing early biomark-
ers of AKI in urine (uNGAL or uIL-18) of 
critically ill children, published in English 
during the 10-year period. Search for pub-
lication was performed in the PubMed da-
tabase.
Results. Analysis included 10 studies that 
investigated early biomarkers of AKI 
(NGAL or IL-18) in urine of critically ill 
children and compared them with sCr. 
Among the biomedical studies analyzed 
in our literature review, 9 measured the 
NGAL level in urine or both in urine and 
serum, while 2measured  IL-18 in urine. 
It was determined that uNGAL and uIL-
18 were good early diagnostic biomarkers 
of AKI, which increased 48 h earlier than 
Cr in serum (P<0.005). The meta-analysis 
carried out by Haase et al. showed that 
uNGAL predicted the development of 
AKI better in critically ill children than in 
adults (OR, 25.4; ROC, 0.930 vs. OR, 10.6; 
ROC, 0.782). Three studies reported that 
the uNGAL level in study populations with 
AKI directly depended on disease severity 
and AKI degree (P<0.005). Four studies 
found that uNGAL and one study that uIL-
18 are good predictive factors of mortality 
(P<0.005).
Conclusions. uNGAL and uIL-18 are early 
predictive biomarkers of AKI in critically 
ill children. uNGAL and uIL-18 level cor-
related well with disease severity and are 
independent predictive biomarkers of 
mortality. 
Key words: acute kidney injury, critically ill 
children, biomarkers, uNGAL, uIL-18.
INTRODUCTION
Acute kidney injury (AKI) is a life-threat-
ening clinical syndrome caused by a sud-
den and rapidly progressing impairment 
of renal function (most commonly revers-
ible), characterized by the retention of ni-
trogenous waste products in blood as well 
as various alterations in fluid, electrolyte 
and acid-base homeostasis. With further 
worsening of AKI, cells undergo necrosis 
and apoptosis, and AKI develops to the 
stage of renal failure. However, up to date, 
there has been a lack of unified standard-
ized criteria defining AKI, and few studies 
have investigated the prevalence of AKI 
and its causes in the pediatric population. 
(1,2) AKI is a common and complicated 
medical problem among hospitalized chil-
dren and diagnosed in 2%-4.5% of the 
children, treated in pediatric intensive care 
units (PICUs). (3,4) According to different 
authors, mortality among children with 
AKI remains high (8% to 89%), despite 
improving patient care and technical pos-
sibilities. (3,5,6) Bailey et al. reported that 
the mortality rate among children who de-
veloped AKI and were treated in the PICUs 
was 11 times higher than that among chil-
dren who did not develop AKI. (4) To date, 
there has been no specific treatment of 
AKI, and only renal replacement therapy 
is applied.
Many authors investigating AKI causes 
have noticed that in 50%-80% of the cases, 
the cause of AKI is not a renal disease, but 
other disease (so-called secondary AKI), 
and such AKI develops as a consequence of 
the main disease. (4,7) Thus, it is very im-
portant to identify the onset of renal dam-
age as early as possible, apply preventive 
measures and adequate treatment in order 
to avoid the development of renal failure, 
reduce pediatric mortality rates, and im-
prove outcomes. (8) Creatinine (Cr) levels 
start to rise only after 2 days when 50% 
of the renal function has been lost. It is a 
functional marker of glomerular filtration 
rate (GFR), but not a marker of damage at a 
cellular level. Cr is considered a late mark-
er of AKI, closely related to patient’s age, 
race, gender, muscle mass, medications or 
hydration status. (9) With recent advances 
in medical science, it has become evident 
that in the beginning, renal damage de-
velops at the molecular level and later, at 
the cellular level. Substances produced by 
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cells (interleukins, proteins, etc.) could be 
early biomarkers of renal damage because 
later, with the progressing process, renal 
insufficiency develops. The stage of renal 
damage is a reversible process, and it is 
possible to prevent the progression of renal 
damage and thus to reduce pediatric mor-
tality rates by its timely detection, adop-
tion of precautionary measures, ensuring 
of appropriate fluid management, and 
avoidance of nephrotoxic factors (medica-
tions or intravenous contrast agents). (10) 
Therefore, modern medicine necessitates 
the identification of novel AKI biomarkers 
that would correlate with renal cell damage 
and could be detected earlier than a rise in 
serum Cr (sCr). (10,11) Novel biomarkers 
of AKI should help diagnose AKI early, its 
location and causes and would allow dif-
ferentiating if the damage was caused by 
a renal disease or other causes. (9) Neu-
trophil gelatinase-associated lipocalin 
(NGAL) and interleukin 18 (IL-18) are one 
of such early markers of AKI. (12,13)
The aim of this literature review was to 
conduct a systematic analysis of studies on 
changes in urinary NGAL (uNGAL) and 
IL-18 (uIL-18) levels among critically ill 
children.
MATERIAL AND METHODS
Criteria for the inclusion of studies in the 
systematic review 
This literature review included the pub-
lications of biomedical studies, assessing 
uNGAL or uIL-18 in critically ill children 
aged from 1 month to 21 years, published 
in English during the 10-year period until 
February 1, 2016. AKI was defined by the 
pediatric Risk, Injury, Failure, Loss and 
End Stage (pRIFLE) criteria created and 
validated by the Acute Dialysis Quality 
Initiative Group. The studies investigating 
NGAL or IL-18 only in plasma, examining 
children after cardiac surgery, or evaluat-
ing the impact of medicines on parameters 
were excluded. Only full-text articles were 
analyzed as abstracts are not sufficient for 
a detailed analysis. The inclusion and ex-
clusion criteria for literature sources are 
shown in table 1.
Strategy of search for publications 
Search for publication was performed in 
the PubMed database. Figure 1 depicts the 
key words for search and the detailed pro-
cess of study identification and selection. 
Figure 1. A flow chart of study search and 
selection for systematic review
AKI, acute kidney injury; IL-18, interleu-
kin 18; NGAL, Neutrophil gelatinase-as-
sociated lipocalin; PICU, pediatric inten-
sive care unit. 
Data systematization and analysis
After a detailed search for publications, a 
total of 10 full-text publications meeting 
all inclusion criteria were identified. This 
literature review included 10 biomedical 
studies, and their analysis was performed 
based on the set aim and objectives. The 
following data were extracted from the 
publications analyzed: general informa-
tion (authors, year, and country) and 
characteristics of studies (design, study 
population, sample size, measurements, 
and results).
RESULTS
This literature review included 10 studies 
that evaluated early biomarkers of renal 
injury (NGAL or IL-18) in the urine of 
critically ill patients and compared these 
biomarkers between two patients’ groups, 
i.e. those who developed and did not de-
velop AKI. The data have been systema-
tized and presented in table 2.
Most of the biomedical studies were car-
ried out in North America (4 in the USA 
and 1 in Canada); 1, in other European 
counties such as Germany, Italy, United 
Kingdom, the Netherlands; and 1 in Tur-
key. A total of 9 prospective cohort studies 
included small sample sizes of critically ill 
patients treated in the PICUs. The median 
number of the patients investigated was 
100 (min, 11; max, 308). A meta-analysis 
conducted by Haase et al. included 19 
studies, which enrolled a considerably 
greater number of the investigated sub-
jects, i.e. 2538 patients. 
Among the biomedical studies analyzed in 
our literature review, 9 studies measured 
the NGAL level in urine or both in urine 
and serum, and 2 studies, IL-18 in urine. 
All the included studies analyzed only the 
data of critically ill patients treated in the 
PICUs and evaluated the changes in uN-
GAL or uIL-18 levels in patients and com-
pared them between the two groups: those 
who developed and did not develop AKI. 
It was determined that uNGAL and uIL-
18 were good early diagnostic biomarkers 
Table 1. Inclusion and exclusion criteria for literature sources 
Variable Inclusion criteria Exclusion criteria
Age 1 month to 21 years Younger than 1 month and older than 21 
years
Study population Critically ill patients, humans Patients after cardiac surgery, with diabetes 
mellitus, systemic connective tissue disease, 
or vasculitis; impact of medications; animals
Markers investigated Urine NGAL and IL-18 Only plasma NGAL, IL-18; other parameters
Language English Other languages
Period Published from January 1, 2006, to February 
1, 2016
Published  before 2006
IL-18, interleukin 18; NGAL, Neutrophil gelatinase-associated lipocalin.
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Table 2. Analysis of biomedical studies
Author Year, 
country
Study design Sample size Biomarkers investigated Outcome
Zappitelli et al. (14) 2007, USA Prospective cohort 
study
140 patients aged 1 
month to 21 years, 
treated in the PICU
uNGAL, sCr uNGAL is an early diagnostic marker of 
AKI development, which increased 48 h 
earlier than sCr (P<0.05)
Washburn et al. (15) 2008, USA Prospective cohort 
study
137 patients aged 1 
month to 21 years, 
treated in the PICU
uIL-18, sCr In patients with AKI, uIL-18 concen-
tration rose earlier than that of sCr 
(OR=3.5, P<0.05)
Haase et al. (16) 2009, 
Germany
Meta-analysis of 
19 studies from 8 
countries
2538 children and 
adults
sNGAL, uNGAL, sCr uNGAL level had a better predictive 
value for AKI in children than adults 
(OR=25.4, 95% CI 8.9-72.2 vs. OR=10.6, 
95% CI 4.8-23.4)
Di Nardo et al.
(17)
2013, Italy Prospective cohort 
study
11 patients  treated 
in the PICU and 10 
healthy children
sNGAL, uNGAL, sCysC, 
uCysC, sCr
uNGAL, sCysC, and
uCysC were significant predictors of 
AKI. sNGAL increased in case of sepsis, 
but did not discriminate patients with 
AKI from those without AKI




32 patients aged 1 
month to 18 years, 
treated in a PICU, 
and 20 healthy 
children
sNGAL, uNGAL, sCysC, 
sCr
uNGAL and sNGAL increase in case 
of AKI and help discriminate intrin-
sic from prerenal AKI (P<0.001 and 
P=0.002)
Wai et al. (19) 2013, USA Prospective cohort 
study
39 patients aged 1 
week to 21 years, 
treated in the PICU, 
and 21 healthy 
children
uNGAL, uFGF-2, uEGF, 
sCr, uCr
uNGAL was a more sensitive biomarker 
to detect AKI in critically ill patients 
than uFGF-2 (P<0.001). ROC analysis 
combining all three biomarkers showed 
a sensitivity of 89% and a specificity of 
89%




22 patients aged 1 
month to 21 years, 
treated in the PICU
sNGAL, uNGAL, sCr, 
CRP 
sNGAL and uNGAL are reliable early 
indicators of AKI. sNGAL can be used 
as an indicator of inflammation
McCaffrey et al. (10) 2015, UK Prospective cohort 
study
49 patients aged 16 
days to 15 years, 
treated in the PICU
sNGAL, uNGAL,
uKIM 1, sCr, sCysC
sNGAL and uNGAL are early and better 
predictors of AKI than sCr. sNGAL 
increased in case of sepsis, but was not 







160 patients aged 1 
month to 18 years, 
treated in the PICU
uNGAL, uIL-18, uKIM-
1, sCysC, uCysC, sCr
sCr cannot be replaced by uCysC to de-
fine AKI. uNGAL and uIL-18 were more 
sensitive for predicting AKI than uCysC 
(AUC 0.78 and 0.62)





100 patients aged 1 
day to 1 year, treated 
in the PICU
uNGAL, uKIM 1, sCr uNGAL and KIM -1 levels at 6-12 h and 
12-24 h after admission to the PICU, 
respectively, were significantly higher in 
patients who developed AKI (P<0.001). 
The uNGAL level increased 48 h earlier 
than the sCr level in 84% of the patients. 
With a cut-off value of >126 ng/mL, 
uNGAL had a sensitivity of 84% and a 
specificity of 86%
AKI, acute kidney injury; Cr, creatinine; CRP, C-reactive protein; CysC, cystatin C; EGF, epithelial growth factor; FGF-2, fibroblast 
growth factor 2; IL-18, interleukin 18; KIM-1, kidney injury molecule 1; NGAL, Neutrophil gelatinase-associated lipocalin, PICU, pedi-
atric intensive care unit; s, serum; u, urine.
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of AKI, which increased 48 h earlier than 
Cr in serum (P<0.005). Among the studies 
analyzed, 3 studies examined newborns as 
well and 1 study, critically ill adults. The 
meta-analysis carried out by Haase et al. 
showed that uNGAL predicted the devel-
opment of AKI better in critically ill chil-
dren than adults (OR, 25.4; ROC, 0.930 
vs. OR, 10.6; ROC, 0.782). (16) Three 
studies investigated uNGAL and sNGAL 
levels in healthy children as well, and all 
of them showed that NGAL levels dif-
fered depending on a child’s age. (17-19) 
Among the publications analyzed, 3 stud-
ies showed associations between the uN-
GAL level and disease severity. (10,14,22) 
Studies have noted that the uNGAL level 
in study populations with AKI directly de-
pends on disease severity and AKI degree 
(P<0.005) (table 3). Among the publica-
tions analyzed, no study investigated the 
relationship between uIL-18 and disease 
severity.
There were 6 studies that investigated the 
associations of uNGAL or uIL-18 with 
patient mortality. Only 1 study analyzed 
uIL-18. Table 4 summarizes the studies 
where the relationship between early AKI 
biomarkers and mortality was evaluated.
Five studies analyzed the changes in uN-
GAL levels depending on patient survival. 
Of them, 4 studies showed that uNGAL 
is a good prognostic marker of mortality. 
Zappitelli et al. did not report a statistical-
ly significant association between uNGAL 
and mortality. (14)
DISCUSSION
Human NGAL is expressed by neutro-
phils, macrophages, and epithelial cells of 
various tissues such as the uterus, prostate, 
salivary glands, lung, trachea, esophagus, 
colon, and kidney. (12) When these cells 
or organs are damaged, NGAL is released 
into systemic circulation (so-called sys-
temic pool). Presence of renal failure and 
reduced GFR lead to a rapidly increasing 
NGAL concentration in systemic circula-
tion. Therefore, the NGAL level in plasma 
can increase due to injury to both the kid-
neys and the parenchymal organs synthe-
sizing NGAL. 
Data on changes in the sNGAL level 
among critically ill children are contradic-
tory. Di Nardo et al. examined children 
with severe sepsis and did not find any 
significant difference in the sNGAL level 
comparing septic children with and with-
out AKI. (17) In 2015, the study by Mc-
Caffrey et al. analyzed 49 patients treated 
in the PICUs, with 12 of them having sep-
sis. The authors reported that the pNGAL 
level was increased in septic patients, but 
its increase did not have any significant 
relationship with the development of AKI 
(P=0.71). (10) An increase in the urinary 
NGAL level directly correlated with renal 
tubular injury. (6) As NGAL is secreted 
into the urine in case of ischemic and ne-
phrotoxic injury to distal and collecting re-
nal tubules and its reabsorption is altered 
in case of injury to proximal tubules, the 
NGAL level in the urine increases (the so-
called renal pool). Therefore, in order to 
determine renal injury, scientists recom-
mend investigating early AKI biomarkers 
excreted with urine because they are more 
Table 3. Studies investigating associations between AKI markers and disease severity
Author Year, country Sample size Biomarkers investigated Outcome
Zappitelli et al. (14) 2007, USA 140 uNGAL, sCr uNGAL level  depended on the severity of AKI (P≤0.05)
Zwiers et al. (22) 2015, The Netherlands 100 uNGAL, uKIM 1, sCr uNGAL and KIM-1 levels depended on the severity of 
AKI (P≤0.018)
McCaffrey et al. (10) 2015, UK 49 pNGAL, uNGAL, uKIM 1, 
sCr, sCystC
pNGAL (P=0.027), uNGAL (P=0.0079), and sCystC 
(P=0.0001) levels were higher with progressing AKI
AKI, acute kidney injury; Cr, creatinine; CysC, cystatin C; KIM-1, kidney injury molecule 1; NGAL, Neutrophil gelatinase-associated 
lipocalin, p, plasma; s, serum; u, urine.
Table 4. Studies investigating associations between AKI markers and outcome
Author Year, country Sample size Markers investigated Outcome 
Zwiers et al. (22) 2015, the Netherlands 100 uNGAL, uKIM 1, sCr The uNGAL level in non-survivors was significantly higher 
than in survivors (P≤0.009)
 Wai et al. (19) 2013, USA 39 uNGAL, uFGF-2, 
uEGF, uCr
Non-survivors had a greater uNGAL level than survivors 
(P=0.006). uNGAL with a cut-off value of 6,808 ng/mg had 
a sensitivity of 80% and specificity of 78.6%
Polat et al. (18) 2013, Turkey 32 sNGAL, uNGAL, 
sCystC, sCr
uNGAL level was significantly higher in patients who died 
than that in those who survived (568±387 vs. 352±366 ng/
mL, P=0.004)
Haase et al. (16) 2009, Germany 2538 sNGAL, uNGAL, sCr Non-survivors had a higher uNGAL level than survivors. 
uNGAL with a cut-off value of 212 ng/mL (121.8-506.7) 
had a sensitivity of 65% and a specificity of 82.6%
Washburn et al. (15) 2008, USA 137 uIL-18, sCr uIL-18 was associated with mortality (OR=1.29, P<0.05)
Zappitelli et al. (14) 2007, USA 140 uNGAL, sCr There was no significant difference in the uNGAL concen-
tration between survivors and non-survivors (P>0.05)
AKI, acute kidney injury; Cr, creatinine; CRP, C-reactive protein; CysC, cystatin C; EGF, epithelial growth factor; FGF-2, fibroblast 
growth factor 2; IL-18, interleukin 18; KIM-1, kidney injury molecule 1; NGAL, Neutrophil gelatinase-associated lipocalin, s, serum; 
u, urine.
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specific to renal injury. (11,14,16-18,20) 
The first prospective study investigating 
NGAL in children who underwent cardiac 
surgery was carried out in 2005. (9) Plasma 
NGAL was measured in 71 patients for 5 
days. The study showed that even within 2 
h after surgery the NGAL level in plasma 
and urine was increased by 10 and 100 
times respectively in patients who subse-
quently developed renal injury 2-3 days 
later. The NGAL level after 2 h in urine 
better correlated with disease outcome and 
treatment duration than the NGAL level in 
plasma. The patient population after car-
diac surgery or with contrast-induced ne-
phropathy represents a more homogenous 
group with a known onset and mechanism 
of renal injury. Therefore, the results ob-
tained in this patients’ group should not be 
compared with those recorded in the criti-
cally ill population treated in the PICUs, 
where neither onset, nor mechanism of 
renal injury is known exactly. The mecha-
nism of AKI development among critically 
ill children varies a lot, and after cardiac 
surgery, the mechanism of ischemic renal 
injury prevails. (9) Scientists have started 
to examine children with other diseases, 
who are at risk of developing AKI. Du et al. 
evaluated five urinary biomarkers of AKI 
in 252 patients who arrived to an emer-
gency center. It was shown that uNGAL, 
uKIM-1, and beta-2 microglobulin had 
good or very good accuracy (AUC >0.7 to 
0.8) to predict patients who developed AKI 
when Cr levels still were within a reference 
range. However, the authors did not in-
vestigate AKI progression in hospitalized 
patients, 823), therefore , the evaluation of 
these biomarkers should in the future be 
available for patients at risk of developing 
AKI, treated in pediatric emergency cent-
ers and PICUs. Bailey et al. examined 985 
patients hospitalized to the PICUs and re-
ported that mortality was 11 times higher 
in patients who developed AKI than those 
who did not develop AKI. (4) Therefore, 
the evaluation of early urinary biomarkers 
of AKI should become a routine test as the 
estimation of troponin in case of myocar-
dial infarction. This would allow reducing 
pediatric mortality and improving disease 
outcomes. Our literature review has ex-
tensively discussed statistically significant 
data providing evidence that uNGAL is a 
good predictive biomarker of AKI, associ-
ated with disease severity and outcomes. 
A study by Cangemi et al. compared uN-
GAL levels between healthy newborns 
and children. This study showed that the 
uNGAL concentration in 25 neonates was 
significantly greater than that in children 
(neonates: mean 44.2 ng/mL, median 
30.3 ng/mL, range 5.2-137.4 ng/mL; chil-
dren: mean 10.2 ng/mL, median 4.6 ng/
mL, range 0.2-146.7 ng/mL; P<0.0001). 
(24) The study evaluating the NGAL, IL-
18 levels in urine of healthy children were 
published in 2015.  Median values were: 
uNGAL (6,6ng/ml; IQR 2,8-17), uIL-18 
(21,6pg/ml; IQR 13,6-32,9). The study 
showed reported that the uNGAL and uIL-
18 levels differ, depending on a child’s age. 
(25) However, the comparison of PICU-
treated children who developed or did not 
develop AKI with healthy children showed 
that critically ill children had a significant-
ly greater uNGAL level than their healthy 
peers (P<0.005). (17-19)
Analysis of inflammatory markers has 
shown that the IL-18 level increases con-
siderably in the urine of critically ill pa-
tients. Scientists have started to assess rela-
tionships between IL-18 and AKI severity 
as well as disease outcome. (13,15) Wash-
burn et al. reported that the urinary IL-18 
level increased most in those critically ill 
children who had more severe AKI. An 
increase in IL-18 after 24 and 48 h from 
the disease onset correlated well with early 
development of AKI and occurred earlier 
than a significant rise in sCr (P=0.008). It 
is not only an early biomarker of AKI, but 
also an independent factor for mortality. 
The authors found a considerably greater 
urinary IL-18 level in children with sepsis. 
(15) 
To date, efficient treatment strategies for 
AKI do not exist even though the relation-
ship between AKI severity and mortality 
is obvious. (3,5,8,22) Therefore, there is a 
need for early AKI biomarkers that would 
help determine AKI etiology, duration, 
and severity and would allow to predict 
disease outcomes. Early diagnosis of AKI 
would allow applying preventive measures 
that would protect patients from the devel-
opment of AKI. Therefore, many nephrol-
ogists-scientists now give priority to this 
area of research. 
CONCLUSIONS
Urinary NGAL and IL-18 are early predic-
tive biomarkers of acute kidney injury in 
critically ill children.
An increased NGAL level in the urine cor-
relates well with disease severity.
Urinary NGAL and IL-18 are early inde-
pendent predictive biomarkers of mortal-
ity in critically ill children.
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